Effect of cessation of highly active antiretroviral therapy during a discordant response: Implications for scheduled therapeutic interruptions

N. Hawley-Foss, G. Mbisa, J. J. Lum, A. A. Pilon, J. B. Angel, G. Garber, Andrew David Badley

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although treatment with combination antiretroviral therapy leads to a reduction in the level of plasma viremia and an improvement in CD4 T cell count for most patients, for a minority of patients, an improvement in CD4 T cell count occurs despite the failure of treatment to suppress viral replication. Recent reports suggest that these discordant improvements in CD4 T cell count may last for months to years and are associated with improved clinical outcomes. In a retrospective observational study, we evaluated the effect of therapy cessation on 8 patients with discordant immunologic responses to therapy and found that improved CD4 T cell responses are dependent upon ongoing drug pressure. If antiretroviral agents that are likely to resuppress the virus are not available, we suggest that patients continue the therapy associated with immunologic improvement to maximize the clinical benefit of the discordant response.

Original languageEnglish (US)
Pages (from-to)344-348
Number of pages5
JournalClinical Infectious Diseases
Volume33
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
CD4 Lymphocyte Count
T-Lymphocytes
Anti-Retroviral Agents
Therapeutics
Viremia
Treatment Failure
Observational Studies
Retrospective Studies
Viruses
Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Effect of cessation of highly active antiretroviral therapy during a discordant response : Implications for scheduled therapeutic interruptions. / Hawley-Foss, N.; Mbisa, G.; Lum, J. J.; Pilon, A. A.; Angel, J. B.; Garber, G.; Badley, Andrew David.

In: Clinical Infectious Diseases, Vol. 33, No. 3, 2001, p. 344-348.

Research output: Contribution to journalArticle

Hawley-Foss, N. ; Mbisa, G. ; Lum, J. J. ; Pilon, A. A. ; Angel, J. B. ; Garber, G. ; Badley, Andrew David. / Effect of cessation of highly active antiretroviral therapy during a discordant response : Implications for scheduled therapeutic interruptions. In: Clinical Infectious Diseases. 2001 ; Vol. 33, No. 3. pp. 344-348.
@article{67441a14737349819eb98017d801aa6c,
title = "Effect of cessation of highly active antiretroviral therapy during a discordant response: Implications for scheduled therapeutic interruptions",
abstract = "Although treatment with combination antiretroviral therapy leads to a reduction in the level of plasma viremia and an improvement in CD4 T cell count for most patients, for a minority of patients, an improvement in CD4 T cell count occurs despite the failure of treatment to suppress viral replication. Recent reports suggest that these discordant improvements in CD4 T cell count may last for months to years and are associated with improved clinical outcomes. In a retrospective observational study, we evaluated the effect of therapy cessation on 8 patients with discordant immunologic responses to therapy and found that improved CD4 T cell responses are dependent upon ongoing drug pressure. If antiretroviral agents that are likely to resuppress the virus are not available, we suggest that patients continue the therapy associated with immunologic improvement to maximize the clinical benefit of the discordant response.",
author = "N. Hawley-Foss and G. Mbisa and Lum, {J. J.} and Pilon, {A. A.} and Angel, {J. B.} and G. Garber and Badley, {Andrew David}",
year = "2001",
doi = "10.1086/321902",
language = "English (US)",
volume = "33",
pages = "344--348",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Effect of cessation of highly active antiretroviral therapy during a discordant response

T2 - Implications for scheduled therapeutic interruptions

AU - Hawley-Foss, N.

AU - Mbisa, G.

AU - Lum, J. J.

AU - Pilon, A. A.

AU - Angel, J. B.

AU - Garber, G.

AU - Badley, Andrew David

PY - 2001

Y1 - 2001

N2 - Although treatment with combination antiretroviral therapy leads to a reduction in the level of plasma viremia and an improvement in CD4 T cell count for most patients, for a minority of patients, an improvement in CD4 T cell count occurs despite the failure of treatment to suppress viral replication. Recent reports suggest that these discordant improvements in CD4 T cell count may last for months to years and are associated with improved clinical outcomes. In a retrospective observational study, we evaluated the effect of therapy cessation on 8 patients with discordant immunologic responses to therapy and found that improved CD4 T cell responses are dependent upon ongoing drug pressure. If antiretroviral agents that are likely to resuppress the virus are not available, we suggest that patients continue the therapy associated with immunologic improvement to maximize the clinical benefit of the discordant response.

AB - Although treatment with combination antiretroviral therapy leads to a reduction in the level of plasma viremia and an improvement in CD4 T cell count for most patients, for a minority of patients, an improvement in CD4 T cell count occurs despite the failure of treatment to suppress viral replication. Recent reports suggest that these discordant improvements in CD4 T cell count may last for months to years and are associated with improved clinical outcomes. In a retrospective observational study, we evaluated the effect of therapy cessation on 8 patients with discordant immunologic responses to therapy and found that improved CD4 T cell responses are dependent upon ongoing drug pressure. If antiretroviral agents that are likely to resuppress the virus are not available, we suggest that patients continue the therapy associated with immunologic improvement to maximize the clinical benefit of the discordant response.

UR - http://www.scopus.com/inward/record.url?scp=0034925905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034925905&partnerID=8YFLogxK

U2 - 10.1086/321902

DO - 10.1086/321902

M3 - Article

C2 - 11438900

AN - SCOPUS:0034925905

VL - 33

SP - 344

EP - 348

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -